Literature DB >> 9892074

Simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry.

B Streel1, C Zimmer, R Sibenaler, A Ceccato.   

Abstract

Quantitative analysis of therapeutic compounds and their metabolites in biological matrix (such as plasma, serum or urine) nowadays requires sensitive and selective methods to allow the determination of concentrations in the ng/ml range. A new on-line LC-MS-MS method using atmospheric pressure chemical ionisation (APCI) as interface for the simultaneous determination of nifedipine (NIF) and its metabolite in human plasma, dehydronifedipine (DNIF) has been developed. The compounds were extracted from plasma using solid-phase extraction (SPE) on disposable extraction cartridges (DECs). The SPE operations were performed automatically by means of a sample processor equipped with a robotic arm (ASPEC system). The DEC filled with phenyl modified silica was first conditioned with methanol and water. The washing step was performed with water. Finally, the analytes were successively eluted with methanol and water. The liquid chromatographic (LC) separation of NIF and DNIF was achieved on a RP-18 stationary phase (4 microm). The mobile phase consisted of methanol-50 mM ammonium acetate solution (50:50, v/v). The LC was then coupled to tandem mass spectrometry with an APCI interface in the positive ion mode. The method developed was validated. The absolute recoveries evaluated over the whole concentration range were 95+/-2% and 95+/-4% for NIF and DNIF, respectively. The method was found to be linear in the 0.5-100 ng/ml concentration range for the two analytes (r2 = 0.999 for both NIF and DNIF). The mean R.S.D. values for repeatability and intermediate precision were 2.9 and 3.0% for NIF and 2.2-4.7% for the metabolite. The method developed was successfully used to investigate the plasma concentration of NIF and DNIF in the pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9892074     DOI: 10.1016/s0378-4347(98)00423-x

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  4 in total

1.  Bioequivalence of nifedipine softgel and capsule in healthy Chinese volunteers by liquid chromatography-mass spectrometry.

Authors:  Jing Zhang; Hao-Jing Song; Fan-Long Bu; Chun-Min Wei; Gui-Yan Yuan; Xiao-Yan Liu; Ben-Jie Wang; Rui-Chen Guo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

2.  Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes.

Authors:  Giovanna Di Nardo; Andrea Fantuzzi; Anastasia Sideri; Paola Panicco; Carlo Sassone; Carlo Giunta; Gianfranco Gilardi
Journal:  J Biol Inorg Chem       Date:  2007-01-18       Impact factor: 3.862

3.  Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study.

Authors:  Essam Ezzeldin; Nisreen F Abo-Talib; Marwa H Tammam; Abdelaaty A Shahat
Journal:  Chem Cent J       Date:  2014-03-11       Impact factor: 4.215

4.  Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains.

Authors:  Ellen K Wasan; Jinying Zhao; Joshua Poteet; Munawar A Mohammed; Jaweria Syeda; Kevin Soulsbury; Jacqueline Cawthray; Amanda Bunyamin; Chi Zhang; Brian M Fahlman; Ed S Krol
Journal:  Pharmaceutics       Date:  2019-11-09       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.